MARKET

TARA

TARA

Protara Therapeutics Inc
NASDAQ
1.620
-0.070
-4.14%
After Hours: 1.600 -0.02 -1.23% 16:07 10/10 EDT
OPEN
1.680
PREV CLOSE
1.690
HIGH
1.747
LOW
1.595
VOLUME
120.87K
TURNOVER
--
52 WEEK HIGH
5.24
52 WEEK LOW
1.040
MARKET CAP
33.42M
P/E (TTM)
-0.5082
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TARA last week (0930-1004)?
Weekly Report · 3d ago
Weekly Report: what happened at TARA last week (0923-0927)?
Weekly Report · 09/30 11:40
Weekly Report: what happened at TARA last week (0916-0920)?
Weekly Report · 09/23 11:39
Weekly Report: what happened at TARA last week (0909-0913)?
Weekly Report · 09/16 11:27
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), MoonLake Immunotherapeutics (MLTX) and Protara Therapeutics (TARA)
TipRanks · 09/12 11:30
Protara Therapeutics Inc: Statement of changes in beneficial ownership of securities
Press release · 09/11 00:12
Protara Therapeutics Announces Results From THRIVE-1, A Study Evaluating The Prevalence Of Choline Deficiency And Liver Injury In Patients Dependent On Parenteral Support; Expects To Dose First Patient In Pivotal PK Trial For IV Choline Chloride In Q1 2025
Benzinga · 09/09 12:09
PROTARA THERAPEUTICS INC - EXPECTS TO DOSE FIRST PATIENT IN PIVOTAL PK TRIAL FOR IV CHOLINE CHLORIDE IN Q1 2025
Reuters · 09/09 12:07
More
About TARA
Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.

Webull offers Protara Therapeutics Inc stock information, including NASDAQ: TARA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TARA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TARA stock methods without spending real money on the virtual paper trading platform.